. 2018 Nov 20;58(8):3135–3146. doi: 10.1007/s00394-018-1858-z

Table 5.

Parameters of mineral metabolism at baseline and study end (12 weeks)

	Baseline visit		Study end		Treatment effect		p value
	Median	IQR	Median	IQR	Between-group differences with 95% CI		p value
25-Hydroxyvitamin D (nmol/l)
Vitamin D (n = 47)	56	44–72	89	83–110	32	23 to 41	< 0.001
Placebo (n = 47)	52	42–63	62	52–76	32	23 to 41	< 0.001
PTH (pg/ml)
Vitamin D (n = 46)	45.4	35.2–58.0	48.6	37.3–60.2	− 0.9	− 5.7 to 4.0	0.727
Placebo (n = 47)	43.1	36.3–55.2	49.9	37.1–58.2	− 0.9	− 5.7 to 4.0	0.727
Serum calcium (mmol/l)
Vitamin D (n = 47)	2.37	2.32–2.44	2.37	2.30–2.44	− 1.7	− 4.2 to 0.9	0.197
Placebo (n = 47)	2.36	2.32–2.42	2.36	2.29–2.41	− 1.7	− 4.2 to 0.9	0.197
Urine calcium (mmol/l)
Vitamin D (n = 46)	2.50	1.19–3.61	2.15	0.96–3.94	− 0.25	− 0.98 to 0.48	0.497
Placebo (n = 46)	2.83	1.5–3.63	2.54	1.61–3.58	− 0.25	− 0.98 to 0.48	0.497

Data are shown as medians and interquartile range. Treatment effects with 95% confidence interval and p values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values